Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848739 · ClinicalTrials.gov registry record · Phase 1
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
A Phase 1 study of Colon Cancer and Metastatic Colon Cancer, sponsored by Sapience Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 11
- Study locations
NCT05848739 is a Phase 1 study of Colon Cancer and Metastatic Colon Cancer that is actively recruiting participants, run by Sapience Therapeutics. The registered enrollment target is 130 participants, below the 4,455-participant average among 97 other Colon Cancer trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT05848739, a Phase 1 study of Colon Cancer and Metastatic Colon Cancer, is actively recruiting participants, sponsored by Sapience Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Conditions Studied
Interventions
- DRUG ST316
- DRUG FOLFIRI regimen & bevacizumab
- DRUG Fruquintinib
- DRUG Lonsurf & bevacizumab
Study Locations (11)
Alabama
- University of Alabama - Birmingham
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Sarah Cannon Research Institute - CO - Denver
Louisiana
- Ochsner Clinic Foundation - New Orleans
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- START Midwest - Grand Rapids
New York
- Westchester Medical Center - Valhalla
North Carolina
- Duke Universtiy - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-06-05 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05848739
The ClinicalTrials.gov registry entry for NCT05848739 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,455-participant average among 97 other Colon Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Sapience Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 4 interventions - of which ST316 is the first listed.
NCT05848739 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05848739 about?
NCT05848739 is a clinical study titled "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors". This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. Th...
What is the current status of trial NCT05848739?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2023-06-05. Estimated completion is 2027-05-31.
What conditions does trial NCT05848739 study?
This clinical trial studies the following conditions: Colon Cancer, Metastatic Colon Cancer.
What interventions are being tested in trial NCT05848739?
The interventions under investigation include: ST316 (DRUG), FOLFIRI regimen & bevacizumab (DRUG), Fruquintinib (DRUG), Lonsurf & bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05848739?
This trial is sponsored by Sapience Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05848739 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
RECRUITING · Phase 1
-
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Study of PHN-012 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.